Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc.
Explore linked clinical trials.5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB | Digestive System Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease, short bowel syndrome | Recruiting | Not applicable | 2026-08-03 | NCT03530852 | |
| A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB | Digestive System Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease, short bowel syndrome | Enrolling by invitation | Not stated | 2026-07-06 | NCT05635747 | |
| Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure | Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, exocrine pancreatic insufficiency, multiple organ dysfunction syndrome, pancreas disorder | Active, not recruiting | Not applicable | 2026-07-01 | NCT05710315 | |
| Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients | Digestive System Diseases, exocrine pancreatic insufficiency, pancreas disorder, pancreatitis | Recruiting | Phase 3 | 2026-05-15 | NCT06691893 | |
| Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis | Digestive System Diseases, pancreas disorder, pancreatitis | Enrolling by invitation | Phase 4 | 2026-05-13 | NCT07583342 |